Valneva SE

AYJ

Company Profile

  • Business description

    Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

  • Contact

    12 ter Quai Perrache
    Bureaux Convergence, Bat. A
    Ilot Saint-Joseph
    Lyon69002
    FRA

    T: +33 478766101

    E: [email protected]

    https://www.valneva.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    674

Stocks News & Analysis

stocks

Eli Lilly receives FDA approval to add another oral GLP-1 to market

Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Which of the 3 giant AI IPOs should you buy?

OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,774.90124.80-1.40%
CAC 407,962.390.000.00%
DAX 4023,168.08130.81-0.56%
Dow JONES (US)46,504.6761.07-0.13%
FTSE 10010,436.2971.500.69%
HKSE25,116.53177.50-0.70%
NASDAQ21,879.1838.230.18%
Nikkei 22553,123.49660.221.26%
NZX 50 Index12,902.1576.280.59%
S&P 5006,582.697.370.11%
S&P/ASX 2008,579.50105.50-1.21%
SSE Composite Index3,919.2929.27-0.74%

Market Movers